Nutritional health care products
JAK MULTI (Oclacitinib Maleate Tablets) is a targeted JAK inhibitor veterinary drug for dogs, designed to control pruritus caused by allergic and atopic dermatitis with rapid absorption and proven efficacy.
Targeted Anti-Itch & Anti-Inflammatory Action
Specifically inhibits JAK1/JAK3-dependent cytokines to effectively relieve pruritus from allergic and atopic dermatitis in dogs.
Rapid Absorption & Stable Bioavailability
High oral bioavailability (89%) with consistent absorption, whether administered with or without food.
Low Impact on Hematopoiesis
Minimal effect on JAK2-dependent cytokines involved in hematopoiesis, reducing interference with blood-related functions.
Two-Stage Dosage Regimen
14-day initial therapy followed by once-daily maintenance dosing, balancing efficacy and long-term use safety.
Precise Strength Options
Available in 3.6mg, 5.4mg and 14mg strengths, enabling tailored dosing for dogs of different weights.
Clear Safety & Handling Guidelines
Comprehensive precautions for use, including age/weight restrictions, infection monitoring and human handling safety.
Generic Name: Oclacitinib Maleate Tablets
Trade Name: JAK MULTI
Oclacitinib Maleate
This product is light brown or brown tablets.
Oclacitinib is a synthetic intracellular non-receptor tyrosine kinase (Janus kinase, JAK for short) inhibitor. It inhibits the function of a variety of pruritogenic cytokines and pro-inflammatory cytokines, as well as cytokines involved in allergy that are dependent on JAK1 or JAK3 enzyme activity. It has little effect on cytokines involved in hematopoiesis that are dependent on JAK2.
After oral administration to dogs, the drug is absorbed rapidly and well. The feeding status of dogs has no significant effect on the absorption rate or extent. Following intravenous and oral administration, the terminal half-life appeared similar with absolute bioavailability of 89%, and with low plasma protein binding rate of 66.3%~69.7%. Oclacitinib is metabolized in the dog to multiple metabolites and one major oxidative metabolite was identified in plasma and urine. Overall the major clearance route is metabolism with minor contributions from renal and biliary elimination.
This drug is not a corticosteroid or an antihistamine. The combined use of this product with glucocorticoids, cyclosporine, or other systemic immunosuppressants has not been evaluated.
For the control of pruritus caused by allergic dermatitis and atopic dermatitis in dogs.
Calculated as C₁₅H₂₃N₅O₂S: 3.6mg, 5.4mg, 14mg
Calculated as oclacitinib.Oral administration: For dogs, 0.4 ~ 0.6 mg per 1 kg of body weight, twice a day for 14 consecutive days, and then once a day for maintenance therapy.
| Body Weight Range (kg) | 3.6mg/Tablet | 5.4mg/Tablet | 16mg/Tablet |
| 3.0 ~ 4.4 | 0.5 | - | - |
| 4.5 ~ 5.9 | - | 0.5 | - |
| 6.0 ~ 8.9 | 1 | - | - |
| 9.0 ~ 13.4 | - | 1 | - |
| 13.5 ~ 19.9 | - | - | 0.5 |
| 20.0 ~ 26.9 | - | 2 | - |
| 27.0 ~ 39.9 | - | - | 1 |
| 40.0 ~ 54.9 | - | - | 1.5 |
| 55.0 ~ 80.0 | - | - | 2 |
May increase susceptibility to infections, including demodicosis, and exacerbation of tumors.
1.2g/tab, 10tabs/box
Store at 20 ~ 25°C, transportable at 15 ~ 40°C.
24 months
